263 related articles for article (PubMed ID: 1543025)
21. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
22. Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas.
Jones TH; Figueroa CD; Smith CM; Cullen DR; Bhoola KD
J Endocrinol; 1992 Jul; 134(1):149-54. PubMed ID: 1500840
[TBL] [Abstract][Full Text] [Related]
23. The role of octreotide (Sandostatin) in non-growth hormone-, non-thyroid-stimulating hormone-, and non-prolactin-secreting adenomas.
Warnet A
Metabolism; 1992 Sep; 41(9 Suppl 2):59-61. PubMed ID: 1325596
[TBL] [Abstract][Full Text] [Related]
24. Effect of bromocriptine, ergotamine and other ergot alkaloids on the hormone secretion and growth of a rat pituitary tumour.
Prysor-Jones RA; Jenkins JS
J Endocrinol; 1980 Jul; 86(1):147-53. PubMed ID: 7430884
[TBL] [Abstract][Full Text] [Related]
25. Normal growth and pubertal development during bromocriptine treatment for a prolactin-secreting pituitary macroadenoma.
Dalzell GW; Atkinson AB; Carson DJ; Sheridan B
Clin Endocrinol (Oxf); 1987 Feb; 26(2):169-72. PubMed ID: 3665115
[TBL] [Abstract][Full Text] [Related]
26. Escape phenomenon after successful bromocriptine and octreotide treatment in thyroid stimulating hormone secreting pituitary adenoma residual tissue.
De Rosa G; Testa A; Giacomini D; Carrozza C
Eur J Cancer; 1994; 30A(2):247-8. PubMed ID: 8155399
[No Abstract] [Full Text] [Related]
27. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
28. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
29. Parenteral bromocriptine in the treatment of hormonally active pituitary tumours.
Benker G; Gieshoff B; Freundlieb O; Windeck R; Schulte HM; Lancranjan I; Reinwein D
Clin Endocrinol (Oxf); 1986 May; 24(5):505-13. PubMed ID: 3791649
[TBL] [Abstract][Full Text] [Related]
30. Preoperative short-term administration of octreotide for facilitating transsphenoidal removal of invasive growth hormone-secreting macroadenomas.
Tachibana E; Saito K; Yoshida J
Neurol Med Chir (Tokyo); 1999 Jul; 39(7):496-9; discussion 499-501. PubMed ID: 10437377
[TBL] [Abstract][Full Text] [Related]
31. Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas.
Eversmann T; Fahlbusch R; Rjosk HK; von Werder K
Acta Endocrinol (Copenh); 1979 Nov; 92(3):413-27. PubMed ID: 574700
[TBL] [Abstract][Full Text] [Related]
32. Pulsatile thyrotropin and prolactin secretion in a patient with a mixed thyrotropin- and prolactin-secreting pituitary adenoma.
Adriaanse R; Brabant G; Endert E; Bemelman FJ; Wiersinga WM
Eur J Endocrinol; 1994 Feb; 130(2):113-20. PubMed ID: 8130883
[TBL] [Abstract][Full Text] [Related]
33. Dramatic and rapid shrinkage of a massive invasive prolactinoma with bromocriptine: a case report.
Clayton RN; Webb J; Heath DA; Dunn PJ; Rolfe EB; Hockley AD
Clin Endocrinol (Oxf); 1985 May; 22(5):573-81. PubMed ID: 4028456
[TBL] [Abstract][Full Text] [Related]
34. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.
Barrow DL; Tindall GT; Kovacs K; Thorner MO; Horvath E; Hoffman JC
J Neurosurg; 1984 Jan; 60(1):1-7. PubMed ID: 6689702
[TBL] [Abstract][Full Text] [Related]
35. Pregnancy after bromocriptine-induced reduction of an extrasellar prolactin-secreting pituitary macroadenoma.
Goodman LA; Chang RJ
Obstet Gynecol; 1984 Sep; 64(3 Suppl):2S-7S. PubMed ID: 6433250
[TBL] [Abstract][Full Text] [Related]
36. Results of continuous long-term intravenous application of octreotide via an implantable pump system in acromegaly resistant to operative and X-ray therapy.
Hildebrandt G; Zierski J; Csecsei G; Mueller HW; Stracke H
Acta Neurochir (Wien); 1992; 117(3-4):160-5. PubMed ID: 1414517
[TBL] [Abstract][Full Text] [Related]
37. Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.
Lindsay JR; Harding JA; Ellis PK; Sheridan B; Atkinson AB
Pituitary; 2003; 6(4):209-14. PubMed ID: 15237932
[TBL] [Abstract][Full Text] [Related]
38. Treatment of prolactinomas and growth hormone-producing adenomas with an injectable bromocriptine retard preparation and a somatostatin analogue delivered by an implantable pump.
Schatz H; Stracke H; Hildebrandt G
Pathol Res Pract; 1988 Sep; 183(5):546-51. PubMed ID: 3237541
[TBL] [Abstract][Full Text] [Related]
39. Morphological changes in bromocriptine-treated pituitary tumours.
Anniko M; Wersäll J
Acta Otolaryngol; 1983; 96(3-4):337-53. PubMed ID: 6637451
[TBL] [Abstract][Full Text] [Related]
40. Bromocriptine treatment of prolactin secreting macroadenomas: a radiological, ophthalmological and endocrinological study.
van 't Verlaat JW; Croughs RJ; Hendriks MJ; Bosma NJ; Nortier JW; Thijssen JH
Acta Endocrinol (Copenh); 1986 Aug; 112(4):487-93. PubMed ID: 3751462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
